Kamada (KMDA) Withdrawal of European MAA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

June 22, 2017 7:01 AM EDT Send to a Friend
Kamada Ltd. (NASDAQ: KMDA) today announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary inhaled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login